Business
Collaboration with US healthcare provider
Collaboration with US healthcare provider.
About this update from Genincode Plc
[{"type":"text","content":"\n\nGENinCode Plc\n(\"GENinCode\" or the \"Company\")\n \nCollaboration with US healthcare provider for CARDIO inCode-Score® testing\nMedStar to start clinical use of CARDIO inCode-Score® polygenic testing to prevent cardiovascular disease\n \nOxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces its collaboration with MedStar Health (\"MedStar\"), a ten-hospital health system in the Washington, D.C. area, to use its CARDIO inCode-Score® (\"CIC-SCORE\") test in primary care for the risk assessment of coronary heart disease (\"CHD\"). Results of the CIC-SCORE test will be combined with the standard American College of Cardiology Atherosclerotic Cardiovascular Disease (ASCVD) Risk Calculator to identify patients who could benefit from earlier preventive treatment.\n \nThe CIC-SCORE test assesses an individual's polygenic (DNA) risk of CHD which, together with their clinical risk, provides a comprehensive risk assessment of CHD. It also addresses the well-recognised need for improvement in CHD standard of care practices.\n \nAs the largest healthcare provider in the Mid-Atlantic, MedStar is an effective incubator for evaluating new clinical applications and through this study, MedStar physicians will provide valuable feedback on the clinical utility of CIC-SCORE in the primary care setting. The clinical utility data generated will support coverage determination and reimbursement for CIC-SCORE with the Centers for Medicare and Medicaid Services (CMS). William Weintraub, MD, Director of Population Health Research at MedStar Health Research Institute and Kristen Miller, PhD, Scientific Director for the National Center for Human Factors in Healthcare at MedStar Health Research Institute, are co-Primary Investigators and Christina Schreiber, DO, a family medicine primary care provider with MedStar, is the physician lead for the study.\n \nThe collaboration with MedStar represents the first major US institution to begin clinically assessing CIC-SCORE, forming part of the Early Access commercial programme now underway.\n \nClinicians have for many years recognised the importance of prior CHD events (e.g. heart attack) within families of their patients because genetic factors contribute to the development of atherosclerosis and a p...